Last reviewed · How we verify
CYCLOGUANIL — Competitive Intelligence Brief
phase 2
Dihydrofolate reductase, Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
CYCLOGUANIL (CYCLOGUANIL). Cycloguanil works by blocking the enzyme dihydrofolate reductase, which is necessary for DNA synthesis in certain cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CYCLOGUANIL TARGET | CYCLOGUANIL | phase 2 | Dihydrofolate reductase, Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CYCLOGUANIL CI watch — RSS
- CYCLOGUANIL CI watch — Atom
- CYCLOGUANIL CI watch — JSON
- CYCLOGUANIL alone — RSS
Cite this brief
Drug Landscape (2026). CYCLOGUANIL — Competitive Intelligence Brief. https://druglandscape.com/ci/cycloguanil. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing